David Couto Mallon

Dr. David Couto Mallon

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2023 in JACC
Verified
Journal Article
Closed access
DMDavid Couto Mallon
David Couto Mallon
LALuis Almenar-Bonet
Luis Almenar-Bonet
EBEduardo Barge-Caballero
Eduardo Barge-Caballero
FHFrancisco José Hernández-Pérez
Francisco José Hernández-Pérez
JGJuan Carlos López-Azor García
Juan Carlos López-Azor García
MCMaria Generosa Crespo-Leiro
Maria Generosa Crespo-Leiro

6 March 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JGJ. Guzman-Bofarull
J. Guzman-Bofarull
EREduard Ródenas-Alesina
Eduard Ródenas-Alesina
YMY. Moayedi
Y. Moayedi
LTL. Truby
L. Truby
MRM. Rivas-Lasarte
M. Rivas-Lasarte
MFMarta Farrero-Torres
Marta Farrero-Torres

11 October 2025 in JACC: Heart Failure
Verified
Journal Article
Closed access
LTLauren K. Truby
Lauren K. Truby
YMYasbanoo Moayedi
Yasbanoo Moayedi
MSMarisa Signorile
Marisa Signorile
CFChun-Po Steve Fan
Chun-Po Steve Fan
FFFarid Foroutan
Farid Foroutan
MFMaryjane Farr
Maryjane Farr

1 January 2018 in Circulation Journal
Verified
Journal Article
Open access
PDF file
GMGrecia M. Marrón-Liñares
Grecia M. Marrón-Liñares
Lucía NúñezLucía Núñez
Lucía Núñez
MCMaría G. Crespo-Leiro
María G. Crespo-Leiro
EÁEloy Álvarez-López
Eloy Álvarez-López
EBEduardo Barge-Caballero
Eduardo Barge-Caballero
MPManuel Hermida Prieto
Manuel Hermida Prieto
Background:Heart transplantation (HT) is a well-established lifesaving treatment for endstage cardiac failure. Antibody-mediated rejection (AMR) represents one of the main problems after HT because of its diagnostic complexity and the poor evidence for supporting treatments. Complement cascade and B-cells play a key role in AMR and contribute to graft damage. This study explored the importance of variants in genes related to complement pathway and B-cell biology in HT and AMR in donors and in donor-recipient pairs.Methods and Results:Genetic variants in 112 genes (51 complement and 61 B-cell biology genes) were analyzed on next-generation sequencing in 28 donor-recipient pairs, 14 recipients with and 14 recipients without AMR. Statistical analysis was performed with SNPStats, R, and EPIDAT3.1. We identified one single nucleotide polymorphism (SNP) in donors in genes related to B-cell biology,interleukin-4 receptor subunitα (p.Ile75Val-IL4Rα), which correlated with the development of AMR. Moreover, in the analysis of recipient-donor genotype discrepancies, we identified another SNP, in this case inadenosine deaminase(ADA; p.Val178(p=)), which was related to B-cell biology, associated with the absence of AMR.Conclusions:Donor polymorphisms and recipient-donor discrepancies in genes related to the biology of B-cells, could have an important role in the development of AMR. In contrast, no variants in donor or in donor-recipient pairs in complement pathways seem to have an impact on AMR.

1 January 2019 in Revista Espanola de Cardiologia
Verified
Journal Article
Open access
DMDavid Couto Mallon
David Couto Mallon
FEFrancisco Estévez-Cid
Francisco Estévez-Cid
MSMiguel Solla-Buceta
Miguel Solla-Buceta
CGCarlos García-Velasco
Carlos García-Velasco
MCMaría G. Crespo-Leiro
María G. Crespo-Leiro
JCJosé Joaquín Cuenca-Castillo
José Joaquín Cuenca-Castillo

23 October 2025 in Clinical Transplantation
Verified
Journal Article
Open access
JGJoan Guzman‐Bofarull
Joan Guzman‐Bofarull
ACAlba Martin Centellas
Alba Martin Centellas
DMDavid Couto Mallon
David Couto Mallon
RBRoger Borràs
Roger Borràs
ALAndrea Arenas Loriente
Andrea Arenas Loriente
MFMarta Farrero-Torres
Marta Farrero-Torres
Introduction: Levosimendan, a calcium‐sensitizing inotropic agent, is used in patients with advanced heart failure (HF) awaiting heart transplantation (HT). Its prolonged effects, due to an active metabolite, may influence post‐transplant vasodilation, particularly when administered shortly before HT. However, its impact on post‐HT complications such as vasoplegia and primary graft dysfunction (PGD) remains unclear. This study aimed to evaluate whether preoperative levosimendan affects these outcomes. Methods: This retrospective, multicenter observational study included adult HT recipients from 2010 to 2022 across three Spanish centers. Patients were grouped based on whether they received levosimendan within 1 month prior to HT. Main outcomes were post‐HT vasoplegia (defined as cardiac index ≥2.5 L/min/m 2 , systemic vascular resistance 20 or norepinephrine administration >0.1 µg/kg/min at 24 h post‐HT) and severe PGD, as defined by the 2014 ISHLT criteria. Secondary outcomes included all‐cause mortality. Subgroup analyses were performed for patients receiving levosimendan within 1 week of HT and by sex. Statistical analyses included propensity score (PS) matching, Kaplan–Meier curves, and multivariate Cox regression models. Results: Among 598 HT recipients, 94 (15.7%) received levosimendan preoperatively. After PS adjustment, no significant differences were found in the incidence of vasoplegia (40.0% vs. 39.2%, OR 0.99, p = 0.98) or severe PGD (10.6% vs. 10.3%, OR 1.25, p = 0.63) between groups. Post‐HT mortality was also not different (HR 0.78, p = 0.37). Vasoplegia did not affect mortality, while severe PGD was linked to higher mortality. Subgroup and sex‐based analyses revealed no significant outcome differences. Conclusions: Pre‐HT levosimendan use was not associated with increased early post‐transplant complications and appears to be a safe strategy. Summary: This study evaluated whether giving levosimendan before HT affects early post‐transplant complications. Among 598 patients, 94 received levosimendan within a month before surgery. Results showed no significant differences in rates of vasoplegia, severe primary graft dysfunction, or mortality. Levosimendan use appears safe in the immediate pre‐transplant setting.